Tetrabenazine Shortage: What Providers and Prescribers Need to Know in 2026

For neurologists, movement disorder specialists, and other clinicians prescribing Tetrabenazine in 2026, a frustrating reality is that "writing the prescription" is only the first step. Patients frequently report difficulty getting their Tetrabenazine filled — not because of a formal FDA-declared shortage, but because of structural issues with how this specialty medication is dispensed and distributed. This guide equips providers with the information needed to anticipate access challenges and support their patients effectively.

Current Supply Status: What Providers Should Know

As of 2026, Tetrabenazine is not on the FDA Drug Shortage Database as a nationally confirmed shortage. Generic tetrabenazine is available from multiple manufacturers, and the original brand, Xenazine (associated with Bausch Health), remains available through specialty channels. The supply problem is one of distribution, not production.

The core issue: Tetrabenazine is a low-volume specialty drug. With Huntington's disease affecting approximately 30,000 Americans, most retail pharmacies fill fewer than a handful of Tetrabenazine prescriptions per year — often none. The result is that standard retail chains frequently don't carry it in inventory, and patients face stock-outs that don't reflect any actual supply disruption.

The Insurance and Prior Authorization Landscape in 2026

Insurance-related delays are among the most common access barriers for Tetrabenazine patients. Providers should be aware of the following:

Prior authorization: Virtually all commercial insurance plans require prior authorization for Tetrabenazine. PA criteria typically require documentation of a confirmed Huntington's disease diagnosis and failed or inadequate response to conservative measures.

Specialty pharmacy mandatory distribution: Many large commercial insurance plans (including Cigna, Aetna, United, Blue Cross Blue Shield) require Tetrabenazine to be dispensed through a designated specialty pharmacy rather than a retail pharmacy. Sending the prescription to a standard retail pharmacy will often result in a rejection.

Medicare Part D: Medicare Part D plans cover Tetrabenazine, but plans vary in tier placement and PA requirements. Patients may face significant cost-sharing before meeting deductibles.

Annual PA renewals: Most plans require annual PA renewal. Lapses in renewal — common for patients who are stable and not frequently in contact with their neurologist — cause prescription fill failures that appear as a stock problem but are actually an administrative one.

CYP2D6 Genotyping: A Clinical Requirement Before High-Dose Prescribing

Providers should be aware that the FDA label for Tetrabenazine requires CYP2D6 genotyping before titrating above 50 mg/day. Patients who are poor CYP2D6 metabolizers have markedly increased exposure to the active metabolites alpha-HTBZ and beta-HTBZ. The label limits:

Poor metabolizers: maximum 50 mg/day (25 mg per dose)

Extensive metabolizers: maximum 100 mg/day (37.5 mg per dose)

Strong CYP2D6 inhibitors — including fluoxetine, paroxetine, and quinidine — significantly increase exposure to active metabolites and should be used cautiously or avoided. If a patient is on a strong CYP2D6 inhibitor, they should be treated as a poor metabolizer for dosing purposes.

The Boxed Warning: Depression and Suicidality

Tetrabenazine carries a boxed warning for depression and suicidal ideation in Huntington's disease patients. In a 12-week clinical trial, 19% of patients treated with Tetrabenazine reported depression or worsening depression versus none in the placebo group. In open-label studies lasting up to 80 weeks, the rate of depression/worsening depression was 35%.

Tetrabenazine is contraindicated in patients who are actively suicidal and in patients with untreated or inadequately treated depression. Providers should screen for depression and suicidality at baseline and monitor closely throughout treatment. Patients, their caregivers, and families should be counseled on these risks.

Clinical Alternatives When Tetrabenazine Is Inaccessible

If Tetrabenazine is truly inaccessible for a patient, the following alternatives should be considered in consultation with the patient:

Deutetrabenazine (Austedo/Austedo XR): FDA-approved for HD chorea and tardive dyskinesia. Can start the day after stopping Tetrabenazine. Not yet generic; manufacturer (Teva) offers patient assistance programs.

Valbenazine (Ingrezza): FDA-approved for HD chorea. Once-daily dosing. Cannot be used concurrently with Tetrabenazine. Neurocrine offers patient support programs.

Off-label antipsychotics: Haloperidol, olanzapine, risperidone — low cost and widely available, but risk of tardive dyskinesia with long-term use. Second/third-line only.

How medfinder Can Help Your Patients

medfinder is a service that calls pharmacies on behalf of patients to locate medications in stock. For Huntington's disease patients — who are often managing complex symptoms and caregiver demands — the burden of calling multiple pharmacies is substantial. Referring patients to medfinder.com/providers can relieve that burden and improve prescription fill rates for your most vulnerable patients.

See also: How to Help Your Patients Find Tetrabenazine in Stock: A Provider's Guide.